# Serialization — Stage 3 Review Packet

> **Stage:** 3 — Brian / ISC Review
>
> **Status:** Awaiting Brian / ISC review decisions — NOT approved for implementation
>
> **Source packet:** [TOPIC_SERIALIZATION_DRAFT_PACKET.md](TOPIC_SERIALIZATION_DRAFT_PACKET.md)

---

## ⛔ Implementation Hold Notice

This Stage 3 review packet is not approved topic content. It must not be implemented in the public app. Antigravity must not populate `/topics/serialization` from this packet. A separate approved `TOPIC_SERIALIZATION.md` file is required before implementation.

---

## Stage 3 Decision Rubric

Stage 3 is not a legal interpretation exercise from scratch. It is a publication-readiness review of Brian / ISC input notes.

For each item, Brian / ISC should decide whether the note is safe, useful, source-supported, and appropriately worded for public topic content.

### Decision Labels

Use exactly one of these five labels for each review item:

#### Approved for public topic copy

Use when the note is accurate enough, source-supported enough, and appropriately worded for the public Serialization page.

#### Revise before public use

Use when the idea is useful, but the wording is too strong, too legalistic, too detailed, too adversarial, or needs senior-leader orientation language.

#### Keep internal only

Use when the note is useful for editorial judgment, QA stress-testing, risk awareness, or implementation planning, but should not appear publicly.

#### Source gap — verify before use

Use when the idea may be right, but the source, currency, enforcement posture, or exact citation needs verification before publication.

#### Exclude

Use when the item is out of scope for this product, too detailed, not useful to the target user, or would expand the app beyond the approved orientation model.

---

### Six Questions for Each Note

1. **Is it source-backed?**
   - If yes, it may be approved or revised.
   - If no or uncertain, mark `Source gap — verify before use`.

2. **Is it useful to a senior supply chain leader?**
   - If yes, keep considering.
   - If no, mark `Exclude` or `Keep internal only`.

3. **Is it phrased as orientation rather than legal determination?**
   - If yes, it may be public.
   - If no, mark `Revise before public use`.

4. **Does it avoid overclaiming?**
   - If yes, it may be public.
   - If it uses strong legal language such as "violation," "liable," "adulterated," "must comply," or "critical violation," mark `Revise before public use` or `Keep internal only` unless Brian intentionally approves that language.

5. **Does it fit the Serialization topic?**
   - If yes, keep.
   - If it belongs more naturally in Packaging, Returns, Recalls, Distribution, or Importer / Distributor Responsibilities, cross-link, move, or exclude.

6. **Is it current enough?**
   - If current enforcement posture matters, mark `Source gap — verify before use` unless Brian / ISC has verified currency.

---

### Suggested Default Classification Guidance

> The following default classifications are guidance for Brian / ISC review. They do not approve content automatically.

#### Usually Approve for Public Topic Copy

- Core DSCSA / FD&C Act §582 source anchoring for US serialization.
- Core FMD / Delegated Regulation (EU) 2016/161 source anchoring for EU safety features.
- GS1 / EPCIS as standards-related context.
- US vs EU model distinction: US track-and-trace / transaction data model vs EU verification and decommissioning model.
- Serialization connections to Packaging, Distribution & 3PLs, Returns, Recalls, and Release & Disposition.
- Supply chain ownership themes such as readiness, partner connectivity, master data coordination, serial range planning, and exception visibility.

#### Usually Revise Before Public Use

- Notes using strong "must" language.
- Lifecycle notes that could read like legal applicability determinations.
- Entity-role notes that should be softened into senior-leader orientation language.
- Highly detailed technical notes that need simplification for public topic copy.

Example transformation:

> **Original:** Must affix product identifiers and initiate the TI / TS data stream.
>
> **Public-oriented direction:** For a US NDA holder or manufacturer role, serialization typically includes ensuring product identifiers are applied and that transaction data can move with the first commercial transaction.

Another example:

> **Original:** Not applicable for serialization or track-and-trace requirements.
>
> **Public-oriented direction:** Serialization is usually not central in preclinical supply unless the company is voluntarily using serialization-like controls for chain-of-custody or future readiness.

#### Usually Keep Internal Only

- NotebookLM / adversarial stress-test notes.
- Notes using phrases such as: "direct violation," "technically adulterated," "liable," "FDA will reject," "critical DSCSA violation."

Suggested public-safe transformation:

> **Common pitfall:** Assuming electronic segregation, release status, or exception handling is sufficient without confirming that the process is controlled, validated where appropriate, and reflected consistently across partner systems.

#### Usually Mark Source Gap — Verify Before Use

- FDA DSCSA Compliance Policy after post-November 2024 stabilization / exemption windows.
- Current FDA enforcement posture for §582(g).
- Recent Warning Letter / 483 themes.
- Current GS1 EPCIS revision in production use.
- EU Commission / EMA Q&A current revisions.
- Industry VRS volume and exception-rate trends.
- State Board of Pharmacy enforcement actions.
- ATP de-listing precedents.

#### Usually Exclude or Defer

- LATAM serialization coverage.
- Russia / EAEU Chestny ZNAK.
- China NMPA serialization.
- Saudi Arabia RSD.

Reason: These may be valuable later, but they are outside the current US/EU Serialization topic scope unless Brian intentionally expands jurisdiction scope.

---

### Conservative Decision Rule

When uncertain, choose the more conservative label.

- **Approved for public topic copy** — only when clearly safe.
- **Revise before public use** — when useful but wording needs work.
- **Keep internal only** — when useful but too sharp, sensitive, or operationally specific.
- **Source gap — verify before use** — when source currency or exact citation is uncertain.
- **Exclude** — when outside current scope.

---

> **How to use the review tables below:** Use the Stage 3 Decision Rubric above to replace "Needs Brian / ISC decision" with one of the five approved decision labels during Brian / ISC review.

## 1. Source Inventory Review

| Source | Brian-Provided Status | Proposed Use | Review Decision | Notes |
|---|---|---|---|---|
| DSCSA (Title II of DQSA) / FD&C Act §582 | Verified | Primary US source | Needs Brian / ISC decision | |
| FMD (Directive 2011/62/EU) and Delegated Regulation (EU) 2016/161 | Verified | Primary EU source | Needs Brian / ISC decision | |
| 21 CFR 201.25 (Linear Barcode Rule) | Verified | Supporting US source | Needs Brian / ISC decision | |
| GS1 General Specifications and EPCIS | Verified | Both-jurisdiction standard | Needs Brian / ISC decision | |
| FDA Product Identifiers Under DSCSA QA | Verified | Supporting US guidance | Needs Brian / ISC decision | |
| FDA Standardization of Data and Documentation Practices for Product Tracing | Verified | Supporting US guidance | Needs Brian / ISC decision | |
| FDA Standards for the Interoperable Exchange of Information for Tracing | Verified | Supporting US guidance | Needs Brian / ISC decision | |
| FDA Wholesale Distributor Verification Requirement for Saleable Returned Drug Product | Verified | Supporting US guidance | Needs Brian / ISC decision | |
| FDA Enhanced Drug Distribution Security at the Package Level Under DSCSA (§582(g)) | Draft reference — verify final form | Supporting US guidance | Needs Brian / ISC decision | Verify final form before publication |
| FDA DSCSA Implementation: Identification of Suspect Product and Notification | Verified | Supporting US guidance | Needs Brian / ISC decision | |
| FDA DSCSA Annual Reporting by Wholesale Distributors and 3PLs | Verified | Supporting US guidance | Needs Brian / ISC decision | |
| FDA DSCSA Compliance Policy (post–Nov 2024 stabilization) | Draft reference — verify enforcement posture | Supporting US guidance | Needs Brian / ISC decision | Verify current enforcement posture |
| 21 CFR 205 — State Licensing of Wholesale Prescription Drug Distributors | Verified | Supporting US regulation | Needs Brian / ISC decision | |
| EMA / European Commission Q&A on Safety Features | Verified | Supporting EU guidance | Needs Brian / ISC decision | |
| EMVO User Requirements Specification and Onboarding documentation | Reference standard | Internal reference | Needs Brian / ISC decision | |
| EU GDP (2013/C 343/01) Chapter 5 — Operations | Verified | Supporting EU standard | Needs Brian / ISC decision | |
| ISO/IEC 16022 (Data Matrix) and ISO/IEC 15415 (print-quality grading) | Reference standard | Internal reference | Needs Brian / ISC decision | |

---

## 2. Supply Chain Ownership Review

| Input Note | Proposed Public Use | Review Decision | Reviewer Notes |
|---|---|---|---|
| EPCIS data exchange: technical onboarding and continuous management of EPCIS connections with 3PLs, wholesalers, and dispensers | Ownership table row | Needs Brian / ISC decision | |
| Physical receipt and verification: executing physical receipt and verifying against electronic TI and TS | Ownership table row | Needs Brian / ISC decision | |
| Quarantine and segregation: immediately physically segregating suspect, illegitimate, expired, or recalled product | Ownership table row | Needs Brian / ISC decision | |
| Master data: NDC and GTIN allocation per GS1 Healthcare GTIN allocation rules; product hierarchy | Ownership table row | Needs Brian / ISC decision | |
| Serial number management: range planning, allocation, no-reuse policy, lot-to-serial reconciliation | Ownership table row | Needs Brian / ISC decision | |
| Line-side execution coordination: oversight of CDMO / CMO print-and-verify and aggregation execution | Ownership table row | Needs Brian / ISC decision | |
| Trading partner connectivity: ATP confirmation per §582(a); T3 capture and transmission | Ownership table row | Needs Brian / ISC decision | |
| Saleable return verification: VRS configuration and operational handling per §582(c)(4)(D) | Ownership table row | Needs Brian / ISC decision | |
| Suspect / illegitimate product handling per §582(c)(4): quarantine, investigation, FDA notification | Ownership table row | Needs Brian / ISC decision | |
| Country reporting: EMVO upload for EU presentations; country-specific portals | Ownership table row | Needs Brian / ISC decision | |
| Recall execution: pulling lot- and serial-level distribution data from serialized records | Ownership table row | Needs Brian / ISC decision | |
| Annual reporting under DSCSA §582(d)(3) for distributors and §584 for 3PLs | Ownership table row | Needs Brian / ISC decision | |

---

## 3. Adjacent Ownership Review

### Quality

| Input Note | Proposed Public Use | Review Decision | Reviewer Notes |
|---|---|---|---|
| Disposition (release / reject) and suspect / illegitimate product investigations | Adjacent ownership note | Needs Brian / ISC decision | |
| CSV / CSA per FDA Computer Software Assurance guidance | Adjacent ownership note | Needs Brian / ISC decision | |
| IQ / OQ / PQ for serialization line equipment | Adjacent ownership note | Needs Brian / ISC decision | |
| Change control on master data, line moves, software releases, vendor migrations | Adjacent ownership note | Needs Brian / ISC decision | |
| Exception and deviation handling | Adjacent ownership note | Needs Brian / ISC decision | |
| Audit and inspection support | Adjacent ownership note | Needs Brian / ISC decision | |

### Regulatory

| Input Note | Proposed Public Use | Review Decision | Reviewer Notes |
|---|---|---|---|
| Notification to authorities — FDA Form 3911 within 24 hours | Adjacent ownership note | Needs Brian / ISC decision | |
| NDC registration; PC (PPN / NTIN) publication for EU | Adjacent ownership note | Needs Brian / ISC decision | |
| EU MAH master-data uploads to EMVO before pack release | Adjacent ownership note | Needs Brian / ISC decision | |
| Country regulatory filings that cite serialization data and labeling | Adjacent ownership note | Needs Brian / ISC decision | |
| Recall communications: serial-driven distribution lookups | Adjacent ownership note | Needs Brian / ISC decision | |

### 3PL / Distributor

| Input Note | Proposed Public Use | Review Decision | Reviewer Notes |
|---|---|---|---|
| Providing warehousing and logistics without taking ownership | Adjacent ownership note | Needs Brian / ISC decision | |
| T3 receipt, storage, downstream transmission per §582(b)(1) and (c)(1) | Adjacent ownership note | Needs Brian / ISC decision | |
| ATP verification at every transaction | Adjacent ownership note | Needs Brian / ISC decision | |
| Saleable return verification per §582(c)(4)(D) | Adjacent ownership note | Needs Brian / ISC decision | |
| Aggregation handling: parent-child integrity at receipt and shipping | Adjacent ownership note | Needs Brian / ISC decision | |
| §582(d)(3) and §584 annual reporting | Adjacent ownership note | Needs Brian / ISC decision | |

### Serialization Provider

| Input Note | Proposed Public Use | Review Decision | Reviewer Notes |
|---|---|---|---|
| VAN routing and maintenance of the serialized data repository | Adjacent ownership note | Needs Brian / ISC decision | |
| Hub services: data normalization, country reporting connectors | Adjacent ownership note | Needs Brian / ISC decision | |
| API / EDI / EPCIS integration with trading partners | Adjacent ownership note | Needs Brian / ISC decision | |
| Master data management within the hub | Adjacent ownership note | Needs Brian / ISC decision | |
| Change management for new country requirements | Adjacent ownership note | Needs Brian / ISC decision | |

### MAH / NDA Holder

| Input Note | Proposed Public Use | Review Decision | Reviewer Notes |
|---|---|---|---|
| Overall responsibility for placing product on market, generating SNI, uploading serial data | Adjacent ownership note | Needs Brian / ISC decision | |
| Master data ownership: NDC / PC, GTIN, product hierarchy, serial range allocation | Adjacent ownership note | Needs Brian / ISC decision | |
| Serialization architecture and policy | Adjacent ownership note | Needs Brian / ISC decision | |
| Service-provider selection and contracting | Adjacent ownership note | Needs Brian / ISC decision | |
| Recall, withdrawal, suspect product responses | Adjacent ownership note | Needs Brian / ISC decision | |
| ATP registration and FDA Establishment Registration | Adjacent ownership note | Needs Brian / ISC decision | |

### CDMO / CMO

| Input Note | Proposed Public Use | Review Decision | Reviewer Notes |
|---|---|---|---|
| Applying physical 2D Data Matrix, linear barcodes, and human-readable interpretations | Adjacent ownership note | Needs Brian / ISC decision | |
| Line equipment serialization capability and qualification | Adjacent ownership note | Needs Brian / ISC decision | |
| Master data exchange with sponsor | Adjacent ownership note | Needs Brian / ISC decision | |
| Quality / Technical Agreement provisions on serialization roles | Adjacent ownership note | Needs Brian / ISC decision | |
| Sponsor sign-off on serialized batches before release | Adjacent ownership note | Needs Brian / ISC decision | |

---

## 4. Jurisdiction Notes Review

### US

| Input Note | Proposed Public Use | Review Decision | Reviewer Notes |
|---|---|---|---|
| Requires 2D Data Matrix on lowest saleable unit encoding NDC, serial, lot, expiry | Jurisdiction comparison | Needs Brian / ISC decision | |
| Track-and-trace model: passing TI and TS between trading partners | Jurisdiction comparison | Needs Brian / ISC decision | |
| Verification triggered on suspect product and saleable returns | Jurisdiction comparison | Needs Brian / ISC decision | |
| ATP regime under §582(a) governs who can transact | Jurisdiction comparison | Needs Brian / ISC decision | |
| Annual reporting for wholesale distributors and 3PLs | Jurisdiction comparison | Needs Brian / ISC decision | |
| 21 CFR 201.25 linear barcode runs concurrently with DSCSA | Jurisdiction comparison | Needs Brian / ISC decision | |
| State Boards of Pharmacy and 21 CFR 205 add state-level layer | Jurisdiction comparison | Needs Brian / ISC decision | |

### EU

| Input Note | Proposed Public Use | Review Decision | Reviewer Notes |
|---|---|---|---|
| UI containing product code, serial, batch, expiry uploaded to EMVS | Jurisdiction comparison | Needs Brian / ISC decision | |
| Endpoint verification and decommissioning at point of dispense | Jurisdiction comparison | Needs Brian / ISC decision | |
| Two safety features: UI plus anti-tampering device (ATD) | Jurisdiction comparison | Needs Brian / ISC decision | |
| Wholesaler verification is risk-based, not mandatory every transaction | Jurisdiction comparison | Needs Brian / ISC decision | |
| MAH uploads UI master data to EMVO before pack release | Jurisdiction comparison | Needs Brian / ISC decision | |
| Live since Feb 9, 2019; ongoing Q&A revisions | Jurisdiction comparison | Needs Brian / ISC decision | |

### Both

| Input Note | Proposed Public Use | Review Decision | Reviewer Notes |
|---|---|---|---|
| Strict master data governance and GS1 standards | Jurisdiction comparison | Needs Brian / ISC decision | |
| 2D GS1 Data Matrix at saleable presentation level | Jurisdiction comparison | Needs Brian / ISC decision | |
| Immediate isolation and reporting of suspected falsified / illegitimate | Jurisdiction comparison | Needs Brian / ISC decision | |
| GS1 EPCIS as dominant event-based exchange standard | Jurisdiction comparison | Needs Brian / ISC decision | |
| Serialization service providers operate across both regimes | Jurisdiction comparison | Needs Brian / ISC decision | |

---

## 5. Entity Role Notes Review

| Entity Role | Input Summary | Proposed Public Use | Review Decision | Reviewer Notes |
|---|---|---|---|---|
| NDA Holder | Affix identifiers, initiate TI/TS, originate first T3, ATP under §581(2)(A) | Entity role profile | Needs Brian / ISC decision | |
| MAH | Upload UI to repositories, manage decommissioning, FMD accountability per member state | Entity role profile | Needs Brian / ISC decision | |
| Licensed US Distributor | ATP verification, T3 capture/storage, saleable return verification, suspect handling, annual reporting | Entity role profile | Needs Brian / ISC decision | |
| Importer | Verify qualitative/quantitative analysis (EU), FDA importer of record (US), PLAIR for pre-launch | Entity role profile | Needs Brian / ISC decision | |
| 3PL | §584 annual reporting, logistics without ownership, ATP, T3 storage not origination | Entity role profile | Needs Brian / ISC decision | |
| CDMO Relationship | Quality/Technical Agreement, manufacturer of record, line equipment, master data exchange, serial range assignment | Entity role profile | Needs Brian / ISC decision | |

---

## 6. Lifecycle Notes Review

| Lifecycle Stage | Input Summary | Proposed Public Use | Review Decision | Reviewer Notes |
|---|---|---|---|---|
| Preclinical | Brian input: Not applicable for serialization or track-and-trace | Lifecycle stage note | Needs Brian / ISC decision | |
| Late-stage Clinical | IMPs require packaging/labeling/QP cert, but commercial serialization not strictly required; some sponsors voluntarily serialize | Lifecycle stage note | Needs Brian / ISC decision | |
| Pre-commercial | Master data setup, GTIN/GLN, NDC, line qualification, service provider selection, EMVO onboarding, ATP registration, pilot runs, quality agreements, SOPs | Lifecycle stage note | Needs Brian / ISC decision | |
| Launch | UI upload to EMVS / T3 data streams at first shipment, trading partner testing, VRS config, recall capability validated | Lifecycle stage note | Needs Brian / ISC decision | |
| Post-commercial | Saleable returns, change management, country expansion, annual reporting, VRS volume, aggregation governance, continuous improvement | Lifecycle stage note | Needs Brian / ISC decision | |

---

## 7. Related Topic Notes Review

| Related Topic | Input Summary | Proposed Public Use | Review Decision | Reviewer Notes |
|---|---|---|---|---|
| Packaging | 2D Data Matrix + linear barcode integrity, print-quality grading, aggregation barcoding, EU ATD interaction | Connected topic note | Needs Brian / ISC decision | |
| Labeling & Artwork | Dual barcoding accommodation, bar code zone reservation, human-readable formatting, multilingual EU constraints | Connected topic note | Needs Brian / ISC decision | |
| Distribution & 3PLs | FEFO with DSCSA checks, ATP verification, warehouse aggregation, saleable return verification | Connected topic note | Needs Brian / ISC decision | |
| Returns | Associate saleable return with original TI/TS, VRS for US, EU decommissioning at dispense | Connected topic note | Needs Brian / ISC decision | |
| Recalls | UI decommissioning in repositories, 24-hour verification protocol, serial-driven targeted recall, 21 CFR Part 7 | Connected topic note | Needs Brian / ISC decision | |
| Importer / Distributor Responsibilities | ATP verification, environmental conditions, importer does not displace trading-partner obligation, DSCSA §582(b) + 21 CFR 205 | Connected topic note | Needs Brian / ISC decision | |
| Release & Disposition Handoffs | Physical receipt to QA, SGTIN range tied to released lot, CMO/CDMO handoff, T3 origination, reject/rework/retain handling | Connected topic note | Needs Brian / ISC decision | |

---

## 8. Internal Editorial Risk Notes Review

> **These are stress-test issues from Brian's editorial review process. They are not public copy.**

| Internal Risk Note | Possible Future Use | Review Decision | Reviewer Notes |
|---|---|---|---|
| EPCIS / ALCOA+ risk: failure to post contemporaneously means product technically adulterated in transit | May inform common pitfall | Needs Brian / ISC decision | |
| Electronic segregation validation risk: unvalidated electronic segregation vs EU GDP Chapter 5 | May inform common pitfall | Needs Brian / ISC decision | |
| QA release status mismatch risk: paper release vs system status causing DSCSA bypass | May inform common pitfall | Needs Brian / ISC decision | |
| 3PL investigation boundary risk: entity taking ownership must complete investigation | May inform what-to-ask-next prompt | Needs Brian / ISC decision | |
| MAH delegation risk: CDMO upload failure makes MAH liable for falsified-status medicines | May inform common pitfall | Needs Brian / ISC decision | |
| Small-footprint barcode exemption risk: FDA rejection if redesign not proven unfeasible | May inform what-to-ask-next prompt | Needs Brian / ISC decision | |
| Manual quarantine risk: unverified stock returned to active inventory during IT failure | May inform common pitfall | Needs Brian / ISC decision | |

---

## 9. Source Gaps and Open Questions Review

### Operational Risk Questions

| Question | Disposition | Review Decision | Reviewer Notes |
|---|---|---|---|
| Commercial override hazards: Quality Agreement with 3PL on manual override | Inform future content or keep internal | Needs Brian / ISC decision | |
| Destruction protocols: who issues financial "Destruction Order" to 3PL | Inform future content or keep internal | Needs Brian / ISC decision | |
| CSP insolvency: data return and 6-year record retention | Inform future content or keep internal | Needs Brian / ISC decision | |

### Regulatory and Source-Landscape Gaps

| Gap | Disposition | Review Decision | Reviewer Notes |
|---|---|---|---|
| Final FDA DSCSA Compliance Policy posture post–Nov 2024 | Source gap — verify before use | Needs Brian / ISC decision | |
| FDA inspection / enforcement patterns for §582(g) | Source gap — verify before use | Needs Brian / ISC decision | |
| Industry VRS volume and exception-rate trends | Source gap — verify before use | Needs Brian / ISC decision | |
| Current GS1 EPCIS revision in production use | Source gap — verify before use | Needs Brian / ISC decision | |
| EU Commission / EMA Q&A revisions on safety features | Source gap — verify before use | Needs Brian / ISC decision | |
| LATAM coverage (Brazil ANVISA, Argentina ANMAT) | Source gap — verify before use | Needs Brian / ISC decision | |
| Russia / EAEU Chestny ZNAK regime | Source gap — verify before use | Needs Brian / ISC decision | |
| China NMPA serialization status | Source gap — verify before use | Needs Brian / ISC decision | |
| Saudi Arabia RSD requirements | Source gap — verify before use | Needs Brian / ISC decision | |
| ATP de-listing precedents | Source gap — verify before use | Needs Brian / ISC decision | |
| State Board of Pharmacy enforcement actions | Source gap — verify before use | Needs Brian / ISC decision | |
| Parallel imports / parallel distribution under EU FMD | Source gap — verify before use | Needs Brian / ISC decision | |

---

## 10. Public-Topic Drafting Decisions

> **For each future public section, what input material is available and what decisions remain.**

### Section 1 — What This Is

- **Available inputs:** 17 source candidates, US vs EU jurisdiction notes, master data and EPCIS context
- **Open decisions:** Which sources appear in the public regulatory chain; how to frame the US track-and-trace vs EU verification distinction
- **Source gaps:** FDA DSCSA Compliance Policy final posture; §582(g) enforcement patterns
- **Brian / ISC approval needed:** Source selection and framing language

### Section 2 — Ownership Boundaries

- **Available inputs:** 12 supply chain ownership themes, 6 adjacent ownership subsections
- **Open decisions:** Granularity of ownership table; which adjacent ownership notes become public-facing
- **Source gaps:** None blocking — ownership notes are operational, not source-dependent
- **Brian / ISC approval needed:** Ownership boundary wording and scope

### Section 3 — Applicability

- **Available inputs:** US (7 bullets), EU (6 bullets), Both (5 bullets); 6 entity role profiles; 5 lifecycle stages
- **Open decisions:** Which entity roles get full profiles vs summary; lifecycle stage detail level
- **Source gaps:** LATAM, Russia, China, Saudi Arabia coverage decisions
- **Brian / ISC approval needed:** Jurisdiction scope, entity role scope, lifecycle detail

### Section 4 — Regulatory Chain

- **Available inputs:** 17 sources spanning Law → Regulation → Standard → Guidance
- **Open decisions:** Which sources form the public chain vs internal reference
- **Source gaps:** 2 draft-reference sources need verification; 12 regulatory landscape gaps
- **Brian / ISC approval needed:** Final source list and chain structure

### Section 5 — What It Touches Next

- **Available inputs:** 7 related-topic subsections with handoff descriptions
- **Open decisions:** Which handoffs are emphasized; connection depth
- **Source gaps:** None blocking for related-topic notes
- **Brian / ISC approval needed:** Handoff wording and emphasis

---

## 11. Brian / ISC Approval Checklist

| # | Review Item | Status |
|---|---|---|
| 1 | Source inventory reviewed — statuses confirmed or corrected | ☐ Not started |
| 2 | Public-use source candidates approved | ☐ Not started |
| 3 | Supply chain ownership boundaries approved | ☐ Not started |
| 4 | Adjacent ownership notes approved | ☐ Not started |
| 5 | US jurisdiction notes approved | ☐ Not started |
| 6 | EU jurisdiction notes approved | ☐ Not started |
| 7 | Entity role notes approved | ☐ Not started |
| 8 | Lifecycle notes approved | ☐ Not started |
| 9 | Related-topic notes approved | ☐ Not started |
| 10 | Internal-only notes separated | ☐ Not started |
| 11 | Source gaps identified and triaged (block vs defer) | ☐ Not started |
| 12 | Public drafting authorized | ☐ Not started |
| 13 | `TOPIC_SERIALIZATION.md` creation authorized | ☐ Not started |

---

## 12. Stage Gate Decision

### Current Stage

**Stage 3 — Brian / ISC Review**

### Gate Requirement

Brian / ISC must complete the approval checklist above and explicitly authorize advancement to Stage 4 (Implementation).

### Decision Options

- **Approve:** All checklist items addressed → create `TOPIC_SERIALIZATION.md`
- **Revise:** Return to Stage 2 with corrections → update draft packet
- **Hold:** Defer pending source gap resolution

---

## ⛔ Implementation Hold Notice

This Stage 3 review packet is not approved topic content. It must not be implemented in the public app. Antigravity must not populate `/topics/serialization` from this packet. A separate approved `TOPIC_SERIALIZATION.md` file is required before implementation.

---

## Revision History

| Date | Change | Author |
|---|---|---|
| Phase 5.2-D | Stage 3 review packet created from Stage 2 draft packet. All review decisions defaulted to "Needs Brian / ISC decision." | System |
| Phase 5.2-D1 | Added Stage 3 decision rubric: 5 decision labels, 6-question framework, default classification guidance, conservative decision rule, and review table usage note. No review decisions pre-classified. | System |
